Qiagen (NYSE:QGEN) Cut to “Equal Weight” at Barclays

Barclays lowered shares of Qiagen (NYSE:QGEN) from an overweight rating to an equal weight rating in a report issued on Wednesday, Marketbeat reports. The firm currently has $53.00 price objective on the stock, down from their previous price objective of $55.00.

A number of other research analysts also recently commented on QGEN. Stifel Nicolaus set a $40.00 target price on shares of Qiagen in a research report on Friday, August 7th. Jefferies Financial Group reiterated a “buy” rating and set a $48.00 price target on shares of Qiagen in a report on Thursday, August 6th. Citigroup reiterated a “neutral” rating and set a $52.00 target price (up from $45.00) on shares of Qiagen in a research report on Monday. Morgan Stanley reissued an “overweight” rating on shares of Qiagen in a research note on Friday, September 11th. Finally, UBS Group began coverage on shares of Qiagen in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, Qiagen has a consensus rating of “Hold” and an average target price of $46.09.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $50.16 on Wednesday. Qiagen has a twelve month low of $32.53 and a twelve month high of $57.81. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The company has a market cap of $10.34 billion, a PE ratio of 20.78, a price-to-earnings-growth ratio of 5.00 and a beta of 0.61. The company’s 50 day moving average is $45.11 and its 200 day moving average is $42.73.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The firm had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. During the same period in the previous year, the business posted $0.60 EPS. The business’s revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, sell-side analysts forecast that Qiagen will post 2.44 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Hilltop National Bank purchased a new stake in Qiagen in the 2nd quarter valued at $50,000. Integrated Wealth Concepts LLC bought a new stake in Qiagen during the second quarter worth about $59,000. Allworth Financial LP increased its position in shares of Qiagen by 20.8% in the second quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after acquiring an additional 317 shares during the period. denkapparat Operations GmbH bought a new stake in shares of Qiagen in the 2nd quarter worth approximately $105,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Qiagen by 46.8% during the first quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after acquiring an additional 876 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.